TMCnet News
PetLife Appoints Initial Executive Management Team(Marketwire Via Acquire Media NewsEdge) BEVERLY HILLS, CA -- (Marketwired) -- 08/21/14 -- PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID), today announced it has appointed its initial executive management team following the Company's recently announced transition to a public company. In the weeks and months ahead, the Company plans to add senior executives to management, the Board of Directors and will form a Scientific Advisory Board. Arthur G. Mikaelian has been appointed President, Chief Executive Officer and a member of the Board of Directors. Bruce Niswander has been appointed Chief Financial Officer. Vivek Ramana has been appointed Chief Medical Officer. Arthur G. Mikaelian BioFor the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology. One of Dr. Mikaelian's greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian's polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky University. He also earned an MBA from the University of Bologna, Italy. Bruce Niswander BioMr. Niswander has had over 30 years of experience in commercializing new, entrepreneurial ventures, and was previously working as Director of Economic Development Initiatives with United Nations affiliate, South-South Corporation. During that association he also created and managed the Global Business Incubator (GBI). Prior to Mr. Niswander's work with the United Nations and GBI he spent six years on the faculty of New York University teaching Technology Entrepreneurship, Entrepreneurial Finance and Managing Intellectual Property. While at the University, Mr. Niswander also served as the director of Technology Transfer and created and served as the on-going manager of 3 very successful business incubators in partnership with NYC Mayor Michael Bloomberg. Prior to moving to New York City he personally created and commercialized six distinct entrepreneurial start-ups. He also functioned as the Manager of Entrepreneurial Initiatives for Battelle Memorial Institute (the largest independent research institute in the world). Mr. Niswander studied chemical engineering at the University of Cincinnati, holds a bachelor's degree in finance (Summa Cum Laude), a Master's degree in Business Administration (MBA) and a juris doctorate (JD) -- from Ohio State University. He has also successfully passed all of the requirements for the designation of Certified Financial Analyst (CFA). Vivek Ramana BioPrior to joining PetLife, Dr. Ramana served as Senior Safety Medical Officer/Senior Medical Director for Ambit Biosciences. In 2008 - 2009, Dr. Ramana served as Senior Medical Director/Therapeutic Area Lead for US Astellas. From 2006 to 2008 he was Chief Medical Officer and President for AdPharma. From 2003 to 2006, he served as Vice President, Medical Services at Ovation Pharmaceuticals. During the early part of Dr. Ramana's career, from 1984 to 2003, Dr. Ramana served as Medical Director of R&D for Pharmaceutical Clinical Research, Inc., which involved joint ventures with BMS, Pfizer, Schering Plough, and Astra Zeneca. Dr. Ramana received his medical degree from the University of Belgrade, Serbia and specialized in Radiation Oncology and Clinical Pathology. Post Graduate studies in Molecular Immunology, Genetics and Molecular Biology from University of New Haven, CT; Post-Doctoral Studies in Clinical Pharmacology, Drug Research & Development and Regulation from TUFTS University in Boston. About Petlife PharmaceuticalsPetLife is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and is a spinoff of Medolife Corp. PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness. PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications. Safe HarborSafe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release. Source: PetLife Pharmaceuticals, Inc. |